Registry of Patients in Shock Treated With Vasopressin

Launched by HOSPITAL UNIVERSITARIO 12 DE OCTUBRE · May 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a hormone called arginine-vasopressin (AVP) in patients experiencing shock, a serious condition where the body is not getting enough blood flow. AVP may help improve blood circulation and reduce the side effects that can come from other medications typically used in these situations. The goal of the study is to gather more information on how well AVP works and its safety for patients in shock, especially those with septic shock, which is a severe infection that affects blood flow.

Adults over 18 years old who are in shock and need vasopressor medications (drugs that help constrict blood vessels) may be eligible to participate. This trial is currently recruiting participants, and they will receive AVP as part of their treatment plan in a hospital setting. It's important to note that patients or their legal representatives must agree to participate in this study. By joining this trial, participants will help researchers understand how AVP can be used safely and effectively in treating shock.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient over 18 years of age who is in shock and requires the administration of vasoconstrictors, to whom vasopressin is administered in the operating theatre and/or critical care unit, according to best clinical practice.
• Exclusion Criteria:
• • Non-consent by patient/legal representatives